Medplus Subsidiary Receives 3 Drug License Suspension Orders in Maharashtra
Medplus' subsidiary, Optival Health Solutions, received three drug license suspension orders in Maharashtra for its stores. The suspensions, lasting five days each, are for alleged violations of the Drugs and Cosmetics Act. Potential revenue loss is estimated at ₹5.96 lakhs (Amravati), ₹2.57 lakhs (Nagpur), and ₹1.64 lakhs (Nagpur). Orders were received on December 13, 2025.
While the suspensions are for a short duration (five days) and specific stores, the cumulative potential revenue loss and the nature of regulatory action suggest a medium impact on operations and financials.
The company's subsidiary has received multiple drug license suspension orders, which will lead to potential revenue loss and operational disruptions.
Medplus Health Services Limited has announced that its subsidiary, Optival Health Solutions Private Limited, has received three suspension orders for drug licenses of stores located in Maharashtra.
The orders pertain to a store in Amravati, Maharashtra, whose drug license has been suspended for five days. This suspension was ordered by the Asst. Commissioner & Licensing authority, Food & Drug Administrations, MH, Amravati, Maharashtra, for alleged violations under Rule 65 of the Drugs and Cosmetics Act, 1940, and Drugs and Cosmetics Rules, 1945. The potential revenue loss from this suspension is estimated at ₹5.96 lakhs.
Additionally, two stores located in Nagpur, Maharashtra, have each had their drug licenses suspended for five days. The orders were issued by the Asst. Commissioner & Licensing authority, Food & Drug Administrations, MH, Nagpur, Maharashtra. The potential revenue loss for the Sakkardara store is estimated at ₹2.57 lakhs, and for the Untkhana Road store, it is ₹1.64 lakhs.
These orders were received on December 13, 2025. The company stated that the details of these matters will be available on the websites of Medplus India, BSE Limited, and the National Stock Exchange of India Ltd.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.